Drugs with Handling Concerns Due to Reproductive Risk
|
|
- Lionel O’Neal’
- 5 years ago
- Views:
Transcription
1 PL Detail-Document # This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER May 2012 Drugs with Handling Concerns Due to Reproductive Risk Drugs that are considered hazardous can be helpful and even lifesaving for the sickest patients. 1 However, these drugs can pose risks to individuals who are exposed to them in a nontherapeutic manner, such as by inhalation or absorption through the skin in the workplace. 1-3 Hazardous drugs may also cause reproductive toxicities such as increased risk of spontaneous abortion, reduced fertility, and fetal harm. 3 Some drugs such as dutasteride and finasteride only have the potential to pose reproductive risks to exposed individuals, and are not otherwise hazardous. Reproductive toxicities may only be demonstrated when a drug is ingested, and sometimes only in animal studies. The risks of occupational exposure may not be clear. Proper hand hygiene is also key. Ingestion of hazardous drugs in the workplace can occur via the hand to mouth route. 2,4 Keep in mind there are a lack of good data on the reproductive risks of handling hazardous drugs using the currently recommended practices and personal protective equipment. 5 The following chart presents suggestions on drug handling for individuals with reproductive concerns. This chart may not be all-inclusive of drugs with reproductive toxicities or exactly reflective of classifications and policies of various pharmacies and organizations. Refer to your pharmacy s policies, consult with your health care provider, and notify your supervisor for further guidance about drug handling. 2,5 Any individual who handles hazardous drugs should receive proper training. 2,3,6 Hazardous Drugs 7,8 (Listed drugs are hazardous to all individuals, in addition to possible reproductive hazards) Antivirals (some) Chemotherapy and A higher risk of (e.g., cidofovir-u.s. other hazardous handle drugs in original packaging or packaged for delivery to spontaneous abortion and [Vistide], entecavir drugs may not only a patient or patient care unit with gloves. 2,7 Use powder-free birth defects has been [Baraclude], ganciclovir harm an individual chemotherapy gloves. 2,4 Double gloving is recommended. 2 seen in nurses who [Cytovene], ribavirin [e.g., who is exposed, but administer Copegus-U.S., Rebetol-U.S., may also cause birth chemotherapy. 1,2,5 Virazole], valganciclovir defects and increase Pregnant should [Valcyte]) the risk of wear powder-free chemotherapy gloves and an N95 surgical generally avoid direct care spontaneous mask when repackaging hazardous drugs (e.g., placing caps or of patients who are abortion, birth tabs from a bulk bottle into prescription bottle, unit-dosing caps receiving aerosolized defects, and or tabs). 2,4,7 Double gloving is recommended. 2 ribavirin (Virazole). 24,25 Chemotherapy infertility. 2,8,9 Refer to U.S. product labeling for specific recommendations. Some institutions may Continued Continued subcategorize hazardous
2 (PL Detail-Document #280513: Page 2 of 5) Hazardous Drugs, 7,8 continued (Listed drugs are hazardous to all individuals, in addition to possible reproductive hazards) Immunosuppressants (e.g., azathioprine [e.g., Imuran], everolimus [e.g., Afinitor], mycophenolate [e.g., only manipulate (e.g., crush or split tablets, reconstitute powders, etc) or compound hazardous drugs in a biological safety cabinet (vertical flow hood) with appropriate garb CellCept]) Miscellaneous (e.g., chloramphenicol, sorafenib, sunitinib, thalidomide) (e.g., gloves, gown, mask) as required for ALL individuals handling these drugs. 2,7 Check your pharmacy s policy. requesting an alternate work assignment is reasonable. 2 drugs. High-risk hazardous and low-risk hazardous is an example. This categorization may depend on the risk of exposure and toxicity. For example, oral dosage forms may be considered low-risk and injectable dosage forms high-risk. 7 Drugs with only reproductive toxicity concerns (and WITH specific handling instructions in product labeling) Ambrisentan 9,11 Letairis-U.S., Volibris-Canada Bosentan 10 Tracleer Endothelin receptor antagonists can cause serious birth defects. The manufacturer of bosentan recommends pregnant not handle crushed or broken tabs or liquid suspension. This information is not included in product labeling. Gloves and a mask should be worn when handling these dosage forms. 10 The manufacturer of ambrisentan does not have the same information, but the same precautions are likely prudent considering the similar reproductive toxicities of the drugs. Dutasteride Avodart, Jalyn Antiandrogenic effect could feminize male fetus Absorbed across skin Women who are or may become pregnant: do not handle capsules. If contact is made with leaking capsules, wash the area immediately with soap and water
3 (PL Detail-Document #280513: Page 3 of 5) Drugs with only reproductive toxicity concerns (and WITH specific handling instructions in product labeling), continued Finasteride Propecia, Proscar Antiandrogenic effect could feminize male fetus Absorbed across skin Women who are or may become pregnant: do not handle crushed or broken tablets. (Finasteride tablets are coated and will prevent contact with the active ingredient during normal handling provided that the tablets have not been broken or crushed.) Testosterone, Topical Androderm, AndroGel, Axiron (U.S.), Fortesta (U.S.), Testim, others Testosterone may cause fetal harm Pregnant : avoid skin contact with gel application sites in men. If unwashed or unclothed skin to which gel has been applied (or unwashed clothing exposed to testosterone gel) comes in direct contact with the skin of a pregnant woman, wash the general area of contact on the woman with soap and water as soon as possible. (In vitro studies show that residual testosterone is removed from the skin surface by washing with soap and water.) 21,22 Pregnant : avoid exposure to used packets, patches, pumps, etc. 22 A study evaluated dermal exposure in female partners of men using AndroGel. Women had skin contact with the application site for 15 min, two to 12 h after application. Serum testosterone levels doubled over baseline. Transfer was prevented by the wearing of a shirt. 21
4 (PL Detail-Document #280513: Page 4 of 5) Drugs with only reproductive toxicity concerns (and WITHOUT specific handling instructions in product labeling) Other Pregnancy Category D and X drugs (e.g., ACE inhibitors, angiotensin receptor blockers, misoprostol, statins, estrogen, etc) Reproductive toxicities with Pregnancy Category D and X drugs vary widely. In addition, their toxicities can vary depending on the stage of pregnancy. Check your pharmacy s policy to find out if there are special handling precautions in place for drugs with the potential to cause reproductive toxicity. Practices that generally reduce exposure to drugs include: Category D and X drugs can cause fetal harm when ingested. However, the risks with occupational exposure (other than those already mentioned) may not be known. 5 Frequent handwashing to prevent hand to mouth exposure to drugs. Wearing chemotherapy gloves when handling capsules, tablets, etc. 4 Adding an N95 mask when crushing tablets, splitting tablets, reconstituting powders, etc. 4 Requesting an alternate work assignment. Topical dosage forms increase the risk for exposure compared with oral dosage forms. 7 Coated tabs or caps pose a lower risk for exposure than uncoated tabs or liquids. 1,5,23 Keep drugs that are unitdosed or available in bottles with quantities for dispensing (e.g., isotretinoin, misoprostol) in their original packaging to reduce exposure. Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.
5 (PL Detail-Document #280513: Page 5 of 5) Project Leader in preparation of this PL Detail- Document: Stacy A. Hester, R.Ph., BCPS, Assistant Editor References 1. CDC. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. September (Accessed April 16, 2012). 2. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. January 12, dlhazdrugs.aspx. (Accessed March 20, 2012). 3. Pharmaceutical compounding-sterile preparations. In: The United States Pharmacopeia, 35th rev., and The National Formulary, 30th ed. Rockville, MD: The United States Pharmacopeial Convention, CDC. Personal protective equipment for health care workers who work with hazardous drugs. October (Accessed April 16, 2012). 5. United States Department of Labor. Controlling Occupational Exposure to Hazardous Drugs. January ml. (Accessed April 16, 2012). 6. Pharmaceutical compounding-nonsterile preparations. In: The United States Pharmacopeia, 35th rev., and The National Formulary, 30th ed. Rockville, MD: The United States Pharmacopeial Convention, University HealthSystem Consortium. UHC consensus statement: model hazardous drug safety plan for institutions. January CDC. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings September (Accessed April 13, 2012). 9. Product information for Letairis. Gilead. Foster City, CA February Personal communication (written). T. White, Pharm.D. Medical Information Department. Actelion Pharmaceuticals. South San Francisco, CA April 13, Product monograph for Volibris. GlaxoSmithKline. Mississauga, ON L5N 6L4. December Product information for Avodart. Research Triangle Park, NC October Product information for Jalyn. GlaxoSmithKline. Research Triangle Park, NC June Product monograph for Avodart. GlaxoSmithKline. Mississauga, ON L5N 6L4. November Product monograph for Jalyn. GlaxoSmithKline. Mississauga, ON L5N 6L4. February Product information for Propecia. Merck. Whitehouse Station, NJ June Product information for Proscar. Merck. Whitehouse Station, NJ January Product monograph for Propecia. Merck Canada. Kirkland, QC H9H 4M7. November Product monograph for Proscar. Merck Canada. Kirkland, QC H9H 4M7. November PL Detail-Document, Secondary Exposure to Topical Hormones. Pharmacist s Letter/Prescriber s Letter. July Product information for AndroGel. Abbott. North Chicago, IL December Product monograph for AndroGel. Abbott. Saint- Laurent, QC H4S 1Z1. January Conner T. Safe handling of hazardous drugs: risks and practical considerations. November (Accessed April 13, 2012). 24. Product information for Virazole. Valeant. Aliso Viejo, CA November Product monograph for Virazole. Valeant Canada. Montreal, QC H4R 2P9. February Cite this document as follows: PL Detail-Document, Drugs with Handling Concerns Due to Reproductive Risk. Pharmacist s Letter/Prescriber s Letter. May Evidence and Recommendations You Can Trust 3120 West March Lane, P.O. Box 8190, Stockton, CA ~ TEL (209) ~ FAX (209) Subscribers to the Letter can get PL Detail-Documents, like this one, on any topic covered in any issue by going to or
Compounding KI for Radiation Exposure
PL Detail-Document #270323 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2011 Compounding KI for
More informationCharacteristics of Transdermal Patches
This Clinical Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER July 2017 ~ Resource #330733 Characteristics of Transdermal
More informationUSP 800 and Hazardous Medications
USP 800 and Hazardous Medications Trung H. Nguyen, PharmD and Alesha Davis, CPhT Dayton VA Medical Center Trung.Nguyen610@va.gov Alesha.Davis@va.gov The speaker has no actual or potential conflict of interest
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationSepsis and Septic Shock: New Definitions for Adults
PL Detail-Document #320424 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2016 Sepsis and Septic
More informationInhaled Corticosteroid Dose Comparison in Asthma
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides
More informationIngredient Listing Qty. Unit NDC # Supplier. q.s. to ml
12/20/2018; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier, USP 10 MU Sucrose, NF 23.00 g Propylene Glycol, USP 7.0 ml Medisca Oral Mix (Flavored Suspending Vehicle) 50.0 ml Medisca
More informationMETHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF
Mary Pack Arthritis Program METHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF Handling of premixed injectable Methotrexate (MTX) by employees who are pregnant, breast-feeding or attempting to reproduce
More informationMycophenolate. Information for Parents/Carers
Mycophenolate Information for Parents/Carers St Michael s C Ward 01 878 4258 01 878 4431 Main Hospital Number 01 878 4200 What is mycophenolate and what is it used for? Mycophenolate is an immunosuppressant
More informationIngredient Listing Qty. Unit NDC # Supplier g
8/16/2018; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Lidocaine, USP 0.400 g Stevia Powder 0.10 g Polyox TM WSR-301 Topical Adhesive Powder* 9.50 g *Formula # F 007 422 available
More informationIngredient Listing Qty. Unit NDC # Supplier ml
8/28/2016; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Progesterone 0.25%/Spironolactone 0.5% Stock Solution 5.00 ml Medisca Foamil Base 45.00 g Alcohol (95%), USP q.s. to
More informationModel Standards for Pharmacy Compounding of Non-Sterile Preparations
Model Standards for Pharmacy Compounding of Non-Sterile Preparations Published with the Guidance Document For Pharmacy Compounding of Non-Sterile Preparations National Association of Pharmacy Regulatory
More informationPATIENT INFORMATION. VALCYTE (Val-site) (valganciclovir) tablets
VALCYTE (Val-site) (valganciclovir) tablets PATIENT INFORMATION 30 VALCYTE (Val-site) (valganciclovir hydrochloride) for oral solution What is the most important information I should know about VALCYTE?
More informationAspirin for the Prevention of Cardiovascular Disease
Detail-Document #250601 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2009 ~ Volume 25 ~ Number 250601 Aspirin for the Prevention of Cardiovascular
More informationDisclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations
49th Annual Meeting Non-Sterile Compounding/ Sunil Jambhekar, B. Pharm., M.S., Ph.D Professor, Pharmaceutical Sciences LECOM Bradenton, School of Pharmacy Bradenton, FL 34211 Disclosure I do not have a
More informationPrescriber and Pharmacy Guide for the Opsumit REMS Program
Prescriber and Pharmacy Guide for the Opsumit REMS Program (Risk Evaluation and Mitigation Strategy) including BOXED WARNING for teratogenicity. Risk of teratogenicity Introduction to Opsumit (macitentan)
More informationPART III: CONSUMER INFORMATION WARNINGS AND PRECAUTIONS. ANDROGEL Testosterone gel 1%
PART III: CONSUMER INFORMATION ANDROGEL Testosterone gel 1% This leaflet is part III of a three-part "Product Monograph" published when ANDROGEL was approved for sale in Canada and is designed specifically
More informationProphylactic Use of Potassium Iodide (KI) in Radiological Emergencies*: Information for Physicians
Prophylactic Use of Potassium Iodide (KI) in Radiological Emergencies*: Information for Physicians * Based on FDA's guidance document on use of KI as a thyroid blocking agent in radiation emergencies 1.
More informationPROPECIA is prescribed for individuals with male pattern baldness.
MK 0906 PAGE 1 PROPECIA (FINASTERIDE 0.2 AND 1 MG) VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Male pattern baldness is a common type of hair loss that develops in many men
More informationSUGGESTED FORMULATION. Lot Number. Expiry Date. Ingredient Listing Qty. Unit NDC # Supplier
9/17/2016; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Aloe Vera (Powder) (Freeze Dried) 0.200 g Tacrolimus 5% Stock Powder Blend 0.600 g Ethoxy Diglycol 1.0 ml Medisca U-Mild
More informationThis letter is to notify you of recent changes to the TAMIFLU product monograph. Please note, additions/changes have been highlighted in yellow.
February 13, 2015 Subject: Revised Product Monograph - TAMIFLU (oseltamivir phosphate) Dear Drug Information / Poison Control Centres, This letter is to notify you of recent changes to the TAMIFLU product
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2020-10 Program Prior Authorization/Medical Necessity PAH Agents Medication Adcirca (tadalafil), Adempas (riociguat), Letairis
More informationMaterial Safety Data Sheet CISPLATIN INJECTION SECTION 2 COMPOSITION, INFORMATION ON INGREDIENTS
Material Safety Data Sheet CISPLATIN INJECTION SECTION 1 - PRODUCT MSDS NAME: Cisplatin Injection, BP SYNONYMS: Cis-Diamminedi-chloroplatinum (II) SECTION 2 COMPOSITION, INFORMATION ON INGREDIENTS Active:
More informationSafety Data Sheet European Format
Safety Data Sheet European Format Preparation Date 05-Jan-2007 Revision Date Revision Number 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Product Name Chemical Name Synonyms
More informationLidocaine Hydrochloride 2%, Metronidazole 2%, Misoprostol % Topical Ointment (Suspension, 30 g) Ingredient Listing Qty. Unit NDC # Supplier
6/18/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Lidocaine Hydrochloride, USP Metronidazole, USP 0.600 g Misoprostol 1% Dispersion, USP 0.072 g Ethoxy Diglycol 3.0 ml
More informationLEARNING MODULE: INFECTION CONTROL BLOODBORNE PATHOGENS ISOLATION PRECAUTIONS PHARMACEUTICAL WASTE
LEARNING MODULE: INFECTION CONTROL BLOODBORNE PATHOGENS ISOLATION PRECAUTIONS PHARMACEUTICAL WASTE For Residents & Instructors ggbha.org Updated 6/18/2018 This learning module must be reviewed by residents
More informationDrug Class Monograph. Policy/Criteria:
Drug Class Monograph Class: Pulmonary Arterial Hypertension Agents Drugs: Adcirca (tadalafil), Adempas (riociguat), Flolan (epoprostenol), Letairis (ambrisentan), Opsumit (macitentan), Orenitram (treprostinil),
More informationSorafenib (Nexavar ) ( sor-af-e-nib )
Sorafenib (Nexavar ) ( sor-af-e-nib ) How the drug is given: by mouth Purpose: To stop the growth of cancer cells in kidney cancer, liver cancer, and other cancers How to take the drug by mouth Take on
More informationGLOVES. Getting a grip on infection control. a complete guide for every exposure level
E D U C A T I O N A L S E R I E S GLOVES Getting a grip on infection control a complete guide for every exposure level TIDI understands that choosing what gloves to wear, how to wear them, and knowing
More informationShingles Vaccine: FAQs
This Clinical Resource gives subscribers additional insight related to the Recommendations published in December 2017 ~ Resource #331201 Shingles Vaccine: FAQs The chart below addresses common clinical
More informationIngredient Listing Qty. Unit NDC # Supplier. Sterile Preparation
4/23/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Nifedipine, USP 0.975 g Silica Gel (Micronized) 0.75 g Medisca SPG Supposi-Base 189.06 g SPECIAL PREPARATORY CONSIDERATIONS
More informationTacrolimus. Information for Parents/Carers
Tacrolimus Information for Parents/Carers St Michael s C Ward 01 878 4258 01 878 4431 Main Hospital Number 01 878 4200 What is tacrolimus and what is it used for? Tacrolimus is an immunosuppressant drug,
More informationTIP NO AEROSOLIZED DRUGS TECHNICAL INFORMATION PAPER NO PURPOSE.
AEROSOLIZED DRUGS TECHNICAL INFORMATION PAPER NO. 56-088-0618 PURPOSE. Healthcare workers risk exposure to exhaled aerosolized drugs along with infectious airborne pathogens during administration and routine
More informationPrescriber and Pharmacy Guide for the Tracleer REMS Program
Prescriber and Pharmacy Guide for the Tracleer REMS Program Please see accompanying full Prescribing Information, including BOXED WARNING for hepatotoxicity and teratogenicity. Introduction to Tracleer
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Amlodipine Besylate Tablets 2.5 mg, 5 mg and 10 mg Lupin Limited Mumbai 400 098 INDIA Lupin
More informationIngredient Listing Qty. Unit NDC # Supplier
3/4/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Lidocaine, USP 3.000 g Prilocaine, USP 3.000 g Tetracaine, USP 1.200 g Stevia Powder 0.10 g Butylated Hydroxytoluene (BHT),
More informationLUPIN LIMITED SAFETY DATA SHEET
LUPIN LIMITED SAFETY DATA SHEET Section 1: Identification Section 1, Identification Material Manufacturer Distributor Doxycycline Capsules USP 50 mg, 75 mg and 100 mg Lupin Limited Goa - 403722 India Lupin
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET SECTION 1 - CHEMICAL PRODUCT(S) AND COMPANY IDENTIFICATION Supplier Name and address: Genlantis, A division of Gene Therapy Systems, Inc. 10190 Telesis Court San Diego, CA 92121
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Ramipril Capsules 1.25 mg, 2.5 mg, 5 mg and 10 mg Lupin Limited Mumbai 400 098 INDIA Lupin
More informationEverolimus (Afinitor )
Everolimus (Afinitor ) ( e-ver-oh-li-mus ) How drug is given: By mouth Purpose: to slow the growth of cancer cells in kidney cancer and other cancers How to take the drug Take with or without food and
More informationBritish Columbia Cancer Agency
Page 1 of 12 A. SCOPE This Policy covers the preparation, administration, and disposal of hazardous drugs. See Cancer Drug Manual Appendix 5 for the Hazardous Drug List. (www.bccancer.bc.ca/hpi/drugdatabase/appendices)
More information6/7/2017 CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE DISCLOSURE OBJECTIVES
CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE John Karwoski, RPh, MBA DISCLOSURE I, John Karwoski, RPH, MBA have business relationships with the companies MOBIUS THERAPEUTICS, LLC, Cubex, and
More informationCompounding Medication Regulations
Association of Professors of Dermatology 2016 Annual Meeting Swissôtel, Chicago, IL Compounding Medication Regulations Christopher Bichakjian, MD Professor of Dermatology Comprehensive Cancer Center and
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Imipramine Hydrochloride Tablets USP 10 mg, 25mg and 50mg Lupin Limited Goa 403 722 INDIA
More informationSTANDARDS FOR PHARMACY COMPOUNDING OF NON-STERILE PREPARATIONS
STANDARDS FOR PHARMACY COMPOUNDING OF NON-STERILE PREPARATIONS ACKNOWLEDGEMENTS The standards in this document are based on the Model Standards for Pharmacy Compounding of Non-Sterile Preparations developed
More informationMATERIAL SAFETY DATA SHEET WILKINSONS GROUT CLEANER
MATERIAL SAFETY DATA SHEET WILKINSONS GROUT CLEANER 1. IDENTIFICATION OF THE PREPARATION AND THE COMPANY: SUBSTANCE NAME: Wilkinsons Grout Cleaner APPLICATIONS: Wilkinsons SUPPLIER: Business Park Abergele
More informationMATERIAL SAFETY DATA SHEET
GlaxoSmithKline (919) 483-2100 PO Box 13398 (919) 483-2700 (24 hour contact) 5 Moore Drive RTP, NC 27709 Effective Date: 07/18/97 MATERIAL SAFETY DATA SHEET SECTION 1: CHEMICAL SUBSTANCE PRODUCT NAME:
More informationIngredient Listing Qty. Unit NDC # Supplier TBD. Sterile Preparation
8/16/2018; Page 1 SUGGESTED FORMULATION Acyclovir, USP Ingredient Listing Qty. Unit NDC # Supplier Mineral Oil (Light), NF 3.0 ml Polyox TM WSR-301 Oral Adhesive Paste* *Formula # F 006 397 available on
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationChantix (Varenicline) and Risk of Cardiovascular Events
PL Detail-Document #270803 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER August 2011 Chantix (Varenicline)
More informationIngredient Listing Qty. Unit NDC # Supplier. Sterile Preparation
6/22/2014; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Estradiol 1% Stock Powder Blend 2.000 g Estriol (Micronized), USP 0.080 g Medisca CapsuBlend -H TBD Sodium Chloride,
More informationHydrocortisone 2%, Hydroquinone 6%, Kojic Acid 4%, Salicylic Acid 4%, Tretinoin 0.01% Topical Gel (Suspension, 20 g)
8/22/2016; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Tretinoin 2% Stock Solution 0.10 ml Hydrocortisone (Micronized), USP 0.400 g Hydroquinone, USP 1.200 g Kojic Acid 0.800
More informationPulmonary Arterial Hypertension Drug Prior Authorization Protocol
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationMATERIAL SAFETY DATA SHEET SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION. Rabies Vaccine, Killed Virus
Merck Animal Health One Merck Dr. Whitehouse Station, NJ 08889 MATERIAL SAFETY DATA SHEET Merck Animal Health urges each user or recipient of this MSDS to read the entire data sheet to become aware of
More informationIngredient Listing Qty. Unit NDC # Supplier. Sterile Preparation
2/8/2014; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Baclofen, USP 1.000 g Cyclobenzaprine Hydrochloride, USP 1.000 g Diclofenac Sodium, USP 1.500 g Lidocaine Hydrochloride,
More informationReference ID:
Medication Guide ANDROGEL (AN DROW JEL) CIII (testosterone gel) 1% Read this Medication Guide that comes with ANDROGEL 1% before you start taking it and each time you get a refill. There may be new information.
More information247 CMR BOARD OF REGISTRATION IN PHARMACY
247 CMR 18.00: NON-STERILE COMPOUNDING Section 18.01: Authority and Purpose 18.02: Non-Sterile Compounding Process 18.03: Non-Sterile Compounding Facility 18.04: Non-Sterile Compounding Equipment 18.05:
More informationMODUS OPERANDI FENTANYL. Control No.: P-693/
Control No.: P-693/09-2017 Requesting country: The United States of America File No.: 2017/202335-1 Date of publication: 13/09/2017 MODUS OPERANDI FENTANYL RISE IN USE, OVERDOSE, AND EXPOSURE TO AN OPIOID
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Doxycycline for Oral Suspension USP, 25 mg/5 ml Manufacturer Distributor Lupin Limited Goa 403722 INDIA. Lupin Pharmaceuticals,
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationALAT - Chapter 4. Occupational Health and Safety. Dr. Carrie Freed, DACLAM, DVM, MLAS
ALAT - Chapter 4 Occupational Health and Safety Dr. Carrie Freed, DACLAM, DVM, MLAS Freed.36@osu.edu, 292-7319 OSHA Every institution with an animal research program must have an occupational health and
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationSafety Data Sheet Product Name: Heparin / PF4 Serum Panel - For In Vitro Diagnostic Use Only
Section 1 Identification Product Name Catalog Numbers Heparin / PF4 Assayed Antibody Serum Panel 4036027, 2 Member QC Panel 4036028, Multi-Member Qualification Panel (6 member) Company Identification AKERS
More informationSAFETY DATA SHEET. Oxycodone Hydrochloride (CII) Capsule, 5mg, 100 count bottle NDC
SAFETY DATA SHEET SECTION 1 - IDENTIFICATION Product Identification: Oxycodone Hydrochloride (CII) Capsule, 5mg, 100 count bottle NDC 64950-901-10 Recommended use and restrictions: Oxycodone Hydrochloride
More informationSTANDARD OPERATING PROCEDURES (SOP) FOR CARCINOGENS
STANDARD OPERATING PROCEDURES (SOP) FOR CARCINOGENS INTRODUCTION: Standard operating procedures (SOP) are intended to provide you with general guidance on how to safely work with a specific class of chemical
More informationSafety Data Sheet. (Coenzyme Q10) Coenzyme Q10 DATE PREPARED: 6/24/2015. Section 1. Product and Company Identification
Section 1. Product and Company Identification Coenzyme Q10 Product Name CAS Number 303-98-0 Parchem - fine & specialty chemicals 415 Huguenot Street New Rochelle, NY 10801 (914) 654-6800 (914) 654-6899
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationMaterial Safety Data Sheet
Material Safety Data Sheet BlueEasy Prestained Protein Marker Cat. No. MWP06 1. IDENTIFICATION OF THE PREPARATION/SUBSTANCE AND OF THE COMPANY 1.1 Preparation Name: BlueEasy Prestained Protein Marker Cat.
More informationPRODUCT MONOGRAPH. Pr VALCYTE. Valganciclovir Film Coated Tablets 450 mg (as valganciclovir hydrochloride)
PRODUCT MONOGRAPH Pr VALCYTE Valganciclovir Film Coated Tablets 450 mg (as valganciclovir hydrochloride) Valganciclovir Powder for Oral Solution 50 mg/ml when reconstituted (as valganciclovir hydrochloride)
More informationPROTECTING FIRST RESPONDERS FROM EXPOSURE TO FENTANYL
PROTECTING FIRST RESPONDERS FROM EXPOSURE TO FENTANYL This document establishes interim guidance for first responders who may be exposed to fentanyl and other related substances while on the job. 1 There
More informationPrescriber Guide for the Letairis REMS Program
LETAIRIS RISK EVALUATION AND MITIGATION STRATEGY (REMS) Prescriber Guide for the Letairis REMS Program Changes to the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program (November 2018) Revised:
More informationMATERIAL SAFETY DATA SHEET SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION
Merck Animal Health One Merck Dr. Whitehouse Station, NJ 08889 MATERIAL SAFETY DATA SHEET Merck Animal Health urges each user or recipient of this MSDS to read the entire data sheet to become aware of
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Pravastatin Sodium Tablets USP 10 mg, 20 mg, 40 mg & 80 mg Lupin Limited Goa 403 722 INDIA.
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other SELEXIPAG UPTRAVI 42922 TREPROSTINIL ORENITRAM ER 40827 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request
More informationLenvatinib (Lenvima ) ( len-va-ti-nib )
Lenvatinib (Lenvima ) ( len-va-ti-nib ) How drug is given: By mouth Purpose: To treat thyroid cancer or other cancers How to take this drug This medicine can be taken with or without food. Take each dose
More informationSafety Data Sheet European Format
Safety Data Sheet European Format Preparation Date 09-Jan-2007 Revision Date Revision Number 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Product Name Common Name Chemical
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationMATERIAL SAFETY DATA SHEET SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION
Merck Animal Health One Merck Dr. Whitehouse Station, NJ 08889 MATERIAL SAFETY DATA SHEET Merck Animal Health urges each user or recipient of this MSDS to read the entire data sheet to become aware of
More informationLeadingAge Florida February 24, 2016
BLOODBORNE PATHOGENS EMPLOYEE HANDBOOK 1 POLICY EMPLOYEE ORIENTATION AND IN-SERVICE TO BLOODBORNE PATHOGENS AWARENESS It is the policy of Healthcare Services Group, Inc., to ensure that all employees with
More informationDabrafenib (Tafinlar )
Dabrafenib (Tafinlar ) ( da-braf-e-nib ) How drug is given: By mouth Purpose: To stop the growth of cancer cells in melanoma and other cancers. How to take this drug Take this medication on an empty stomach
More informationMaterial Safety Data Sheet
Material Safety Data Sheet 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION TEVA Pharmaceuticals 650 Cathill Rd PO Box 904 Sellersville, PA 18960 Date Approved: Date Last Revision: Telephone Number: 215-591-3000
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Gatifloxacin Ophthalmic Solution 0.5% Lupin Limited Pithampur (M. P.), 454 775 India. Lupin
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationBloodborne Pathogens Training (OHS_BIO500) Course Material
Introduction (OHS_BIO500) Course Material Welcome to the Bloodborne Pathogens (BBP) Training Course (OHS_BIO500). UAB Campus Employees whose job duties put them at increased risk for exposure to bloodborne
More information1. IDENTIFICATION OF THE PREPARATION/SUBSTANCE AND OF THE COMPANY Preparation Name: Taq DNA polymerase
Taq DNA polymerase 1. IDENTIFICATION OF THE PREPARATION/SUBSTANCE AND OF THE COMPANY Preparation Name: Taq DNA polymerase Use of the preparation: For laboratory use. Suitable for use as molecular weight
More informationSolvents at Work. Exposure to solvents can have both short- and long-term health effects on workers.
Solvents at Work Solvents are among the most commonly used chemicals in workplaces. Workers in different jobs regularly use solvents for degreasing, metal cleaning, adhesion and as paint thinners or lubricants.
More informationIngredient Listing Qty. Unit NDC # Supplier g. Sterile Preparation
Note: Glucosamine Sulfate Potassium Chloride 1267 mg is equivalent to Glucosamine 750 mg. 11/8/2016; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Chondroitin Sulfate Sodium,
More informationEltrombopag (Promacta )
Eltrombopag (Promacta ) ( el TROM boe pag ) How drug is given: By mouth Purpose: to treat aplastic anemia and increase low platelet counts in some conditions How to take this drug 1. Take this medication
More informationPrevention and Treatment of Oral Mucositis
PL Detail-Document #301105 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER November 2014 Prevention and
More informationMATERIAL SAFETY DATA SHEET RILEXINE (cephalexin monohydrate) Chewable Tablets
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATIONS AND OF THE COMPANY UNDERTAKING Product Name Product Description Chewable antibiotic tablets for dogs Manufacturer/Supplier Virbac
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Divalproex Sodium Delayed-Release Tablets USP 125 mg, 250 mg & 500 mg Manufacturer Lupin Limited Mumbai 400 098 INDIA
More informationPulpdent Corporation Revision Date: January 1, 2014
1.0 Commercial Product Name and Supplier 1.1 Commercial product name / designation Kool-Dam Heatless Liquid Dam & Block Out Resin 1.2 1.2.2 1.2.3 Application / Use SIC Use Category Dental material for
More information1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING
SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING Product identifier Details of the supplier of the safety data sheet : ASTRAZENECA PTY LTD PO Box 131 Alma Road,
More informationMaterial Safety Data Sheet. Mitomycin for Injection
Material Safety Data Sheet Mitomycin for Injection SECTION 1 - PRODUCT MSDS ME: Mitomycin for Injection SYNONYMS: mitomycin-c SECTION 2 COMPOSITION, INFORMATION ON INGREDIENTS ACTIVE: Mitomycin ICTIVE:
More informationPackage leaflet: Information for the patient. Avodart 0.5 mg soft capsules dutasteride
Package leaflet: Information for the patient Avodart 0.5 mg soft capsules dutasteride Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. Finasterid Actavis 5 mg film coated tablets. Finasteride
PACKAGE LEAFLET 1 Package leaflet: Information for the user 5 mg film coated tablets Finasteride Read all of this leaflet carefully before you start taking this medicine because it contains important information
More information